APA (7th ed.) Citation

C, W., BC, J., HF, L., EW, S., B, v. d. B., AY, D., . . . PA, v. D. (2021). Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): A double-blind, randomised, placebo-controlled trial. The Lancet. Neurology, 20(4), 275. https://doi.org/10.1016/S1474-4422(20)30494-4

Chicago Style (17th ed.) Citation

C, Walgaard, et al. "Second Intravenous Immunoglobulin Dose in Patients with Guillain-Barré Syndrome with Poor Prognosis (SID-GBS): A Double-blind, Randomised, Placebo-controlled Trial." The Lancet. Neurology 20, no. 4 (2021): 275. https://doi.org/10.1016/S1474-4422(20)30494-4.

MLA (9th ed.) Citation

C, Walgaard, et al. "Second Intravenous Immunoglobulin Dose in Patients with Guillain-Barré Syndrome with Poor Prognosis (SID-GBS): A Double-blind, Randomised, Placebo-controlled Trial." The Lancet. Neurology, vol. 20, no. 4, 2021, p. 275, https://doi.org/10.1016/S1474-4422(20)30494-4.